I was thinking about a program to solve Sudoku.You fill a 9x9 grid with numbers from 1 to 9. The same number must not be ...

Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...

Recursion Pharmaceuticals reported past pipeline and collaboration progress, including positive REC-4881 and REC-1245 trial ...

Sanofi selected its first drug development candidate under its collaboration with Recursion.

Recursion Pharmaceuticals (RXRX) just moved onto many investors’ radar after Sanofi optioned the first development candidate ...

Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology ...

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...

Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a ...

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...